日本患者由来がんモデル学会　学術集会 2026

大会長 近藤格

国立がん研究センター研究所 希少がん研究分野 分野長

Welcome Address from the Conference Chair:

We are delighted to host the Annual Meeting of the Japanese Society for Patient-Derived Cancer Models once again this year. We extend our deepest gratitude to all of you for your participation. The Japanese Society for Patient-Derived Cancer Models was established as a forum for researchers engaged in the establishment and application of cancer models using clinical specimens to share their daily research findings and novel ideas, and to inspire one another.

Up to the present, cancer models such as cell lines, xenografts, and organoids have evolved into an indispensable research foundation for understanding cancer pathology, elucidating the functions of target molecules, and evaluating efficacy in drug discovery. In recent years, driven by the rapid advancement of comprehensive molecular profiling technologies and data science, alongside the emergence of novel therapeutics, the landscape surrounding cancer models has changed dramatically. Today, cancer models are increasingly expected to move beyond the "mere reproduction of disease states" and serve as a common infrastructure that drives international collaborative research and data platforms. Furthermore, in light of the establishment of global standards and the latest regulatory trends in the US and Europe, we have reached a turning point where the positioning and practical implementation of cancer models must be redefined.

The theme of this year's academic meeting is "Envisioning the Future of Cancer Models." Have the highly functional models required by next-generation, data-driven research and international standards been sufficiently developed and implemented in practice? We hope this meeting will provide an opportunity for basic researchers, clinicians, and corporate R&D professionals to transcend their respective standpoints, re-evaluate the possibilities and limitations of diverse models from international and regulatory perspectives, and discuss the technological innovations and conceptual shifts that will be needed in the future.

We sincerely hope that this meeting, through vigorous exchange of opinions, will serve as a catalyst for forging new industry-academia collaborations and jointly mapping out a vision for next-generation research and development, ultimately leading to the further advancement of patient-derived cancer models.

Chairperson Tadashi Kondo